We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for cemiplimab (Sanofi-Aventis Australia Pty Ltd)
Active ingredients
cemiplimab
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
For the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy.
Therapeutic area
Oncology